BioWorld-International-2008-09-17
Blocking Heat Shock Proteins Points to More Selective Drugs
Cell Medica Begins Study of CMV Transplant Therapy
LONDON - Cell Medica Ltd. has treated the first patient in a Phase III trial of a cell therapy treatment for the prevention of cytomegalovirus (CMV) infection in immunocompromised bone marrow transplant patients. (BioWorld International)

